ClinConnect ClinConnect Logo
Search / Trial NCT06897098

Regeneration of Knee and Ankle Cartilage from Autologous Cartilage Mini-grafts (from the Patient's Own Cells)

Launched by VANARIX SA · Mar 19, 2025

Trial Information

Current as of April 23, 2025

Active, not recruiting

Keywords

Cartilage Repair

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Key inclusion criteria:
  • Cartilage focal lesion(s) ≥ 1.5 cm2 and ≤ 10 cm2
  • ICRS grade 3 or 4
  • Pain for 3 months or more
  • Aged over 18 years
  • Key exclusion criteria
  • Inability to undergo MRI
  • Cartilage specific surgery within 12 months from baseline
  • Cartilage therapeutic injection within 3 months from baseline
  • Radiologically apparent degenerative joint disease (K\&L grade \>1)
  • Chronic inflammatory arthritis and/or infectious arthritis

About Vanarix Sa

Vanarix SA is a clinical research organization dedicated to advancing innovative healthcare solutions through rigorous clinical trials. With a focus on developing cutting-edge therapies and medical interventions, Vanarix SA collaborates with pharmaceutical companies, biotechnology firms, and academic institutions to bring new treatments to market. The organization prides itself on its commitment to scientific integrity, patient safety, and regulatory compliance, ensuring that all trials are conducted to the highest ethical standards. Through its expertise in trial design, patient recruitment, and data management, Vanarix SA plays a pivotal role in transforming scientific discoveries into effective healthcare solutions.

Locations

Geneva, , Switzerland

Lugano, Ticino, Switzerland

Geneva, , Switzerland

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported